文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

基因治疗时代下,异基因移植治疗镰状细胞病是否仍有意义?

Is allogeneic transplantation for sickle cell disease still relevant in the era of gene therapy?
PubMed 文献 · Blood Adv · 2025-01-01

镰状细胞病(SCD)是最常见的遗传性血液病,尽管支持治疗改善了欧美儿童的生存,成人仍面临高致残和早死风险。美国FDA已批准两种基因疗法,可能短期减少急性血管闭塞性疼痛事件;异基因造血干细胞移植(allo-HCT)也可治愈,但受供者缺乏、移植物抗宿主病、移植物排斥和死亡风险限制,近期进展减轻了这些障碍。本文讨论SCD治愈性治疗的现状,指出基因疗法和allo-HCT均可能治愈多数患者,但基因疗法费用约高5倍、目前仍需清髓且相关远期健康影响可能使其不如allo-HCT有利。

要点

  • SCD成人仍有高致残和早死风险,儿童生存因支持治疗改善。
  • FDA批准的基因疗法可能短期减少急性血管闭塞性疼痛事件。
  • allo-HCT可治愈SCD,近期进展减轻了供者缺乏、GVHD等障碍。

核心结论

  • 基因疗法和allo-HCT均可能治愈多数SCD患者,但基因疗法费用约高5倍、目前需清髓及相关远期健康影响可能使其不如allo-HCT有利。

研究设计与样本

  • 本文为综述,讨论SCD治愈性治疗的现状。

主要发现

  • SCD是美国和欧洲最常见的遗传性血液病,支持治疗改善了儿童生存,但成人仍有高致残和早死风险。
  • 美国FDA批准的两种基因疗法可能短期减少急性血管闭塞性疼痛事件,若非治愈。
  • allo-HCT可治愈SCD,但受供者缺乏、GVHD、移植物排斥和死亡风险限制,近期进展减轻了这些障碍。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sickle cell disease (SCD) is the most common inherited blood disease. Disease-modifying therapy and supportive care have improved the survival of children with SCD in the United States and Europe. Yet, adults with SCD continue to have high risks of morbidity and early death. Recently, 2 US Food and Drug Administration-approved genetic therapies offer the potential for a short-term decrease in acute vaso-occlusive pain events if not cure. Allogeneic hematopoietic cell transplantation (allo-HCT) is also curative but, until recently, was constrained by limited donor availability and the risks of graft-versus-host disease, graft rejection, and death. Importantly, recent advances have attenuated these barriers. Here, we discuss the current state of therapies with curative intent for SCD. Both genetic therapy and allo-HCT offer the potential for cure for most with SCD. However, the cost (∼5 times higher), the current need for myeloablation, and associated late-health effects may make genetic therapies less favorable choices than allo-HCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Jones RJ, Kassim AA, Brodsky RA, et al. Is allogeneic transplantation for sickle cell disease still relevant in the era of gene therapy? Blood Adv. 2025. PMID: 39602668. doi:10.1182/bloodadvances.2024013693

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。